Kornimate/medical-research-clean huggingface dataset:
impact study of minnesota snap-ed health and nutrition education programs

Conditions: Obesity; Child

Summary: supplemental nutrition assistance program - education (snap-ed) is a national initiative with the goal of improving the health and wellbeing of low income families. university of minnesota extension every year offers nearly 4000 educational events, serving approximately 70,000 minnesotans through the program. extension is conducting an impact study to determine program effectiveness and assess sustained changes of participants and their families that can be directly attributed to programming on a larger and methodically sound scale.


Eligibility criteria:
inclusion criteria: * third grade elementary students * schools that are eligible for snap ed funding (have more than 50% students received free/reduced lunch) exclusion criteria: * other grade elementary students * schools that are not eligible for snap ed funding

Keywords: fruit vegetables motor activity
fruit and vegetables and outcomes after removal of impacted teeth

Conditions: Postoperative Morbidity; Trauma; Wound Healing

Summary: the proposed study will test the following hypotheses: 1. pre-operative daily dual supplementation with juice plus+ (fruit \& vegetable) for 11 weeks will result in reduced post-operative morbidity in terms of quality of life, pain and trismus after 1 week following surgical removal of lower third molars, when compared to placebo. 2. pre-operative daily dual supplementation with juice plus+ (fruit \& vegetable) for 11 weeks will reduce serum markers of oxidative stress, following surgical removal of lower third molars, when compared with placebo.

in general antioxidant status appears to influence wound healing in humans and in animal models of acute trauma, with low antioxidant concentrations and excessive oxidative stress being associated with impaired healing. whilst antioxidant supplementation has been reported to improve plasma antioxidant status and wound healing in animal models of acute trauma, there is remarkably little data from human studies. the use of juice plus+ has been reported to increase serum concentrations of important antioxidants and reduce serum markers of oxidative stress. however, to date there are no reported studies concerning the potential for juice plus+ to improve patient-based outcome measures following the surgical removal of lower third molars. this study therefore proposes to investigate the impact of daily supplementation with juice plus+, in improving outcomes following surgical trauma. while the rationale for the proposed study is primarily predicated on the established role of oxidative stress and antioxidant micronutrients in chronic inflammatory diseases, the proposed randomized controlled clinical study represents an efficient way of evaluating the potential for adjunctive juice plus+ use in improving wound healing and reducing post-operative morbidity following surgical procedures on humans.

Eligibility criteria:
inclusion criteria: 1. patient requiring surgical removal of a single (unilateral) mandibular wisdom tooth 2. tooth requiring full mucoperiosteal flap to be raised for removal 3. bone removal necessary during procedure. exclusion criteria: 1. patients refusing to give written informed consent 2. clinically significant or unstable physical or mental disability rendering the participants incapable of complying with the study protocol as judged by the investigator 3. pregnant or breast-feeding women 4. patients taking long term anti-microbial or anti-inflammatory drugs 5. patients unable to swallow juice plus capsules 6. patients taking regular vitamin or mineral supplementation 7. patients requiring pre-operative antibiotics for surgery 8. patients requiring concomitant extractions or contralateral lower 3rd molar removal 9. allergic to any of the ingredients contained in supplements or placebo medication.

Keywords: third molar trauma pain wound healing post operative morbidity acute trauma short-term wound healing
risk of metabolic adaptation after weight loss

Conditions: Weight Loss; Obesity

Summary: this study aims at identifying the neurohormonal biomarkers that characterize individuals at risk of greater metabolic adaptation to weight loss, a disproportionate decline in resting metabolic rate during and after weight loss.


Eligibility criteria:
inclusion criteria: bmi \> or = 30 any ethnicity exclusion criteria: weight \> or = 400 lbs. diabetes (type 2 or type 1) hypertension heart disease kidney disease liver disease active cancer post solid organ or bone marrow transplant hiv/aids pregnancy breastfeeding current smoker current recreational drug use

Keywords: resting metabolic rate metabolic adaptation
primary tumor harvest for the purpose of possible use in a future clinical trial in patients with ovarian, fallopian tube or primary peritoneal cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Summary: the purpose of this research study is to collect tumor samples at the time of surgery and store them for possible use as part of an experimental vaccine study for the participants cancer in the future.

* even if tumor sample is collected, the participant is under no obligation to participate in the vaccine study. * participants will have their regularly planned surgery as described by their surgeon. during the surgery, tumor samples will be collected. we will only collect tumor that is not needed and could otherwise be thrown away. * the tumor samples will be frozen and placed in storage for up to two years.

Eligibility criteria:
inclusion criteria: * clinical suspicion of advanced ovarian, fallopian tube or primary peritoneal cancer as determined by a gynecologic oncologist * patients are planning to undergo primary or secondary debulking surgery as part of standard of care for their disease * estimated life expectancy of 6 months or greater * 18 years of age or older exclusion criteria: * more than one prior chemotherapy regimen * serious intercurrent illness such as infection requiring iv antibiotics, or significant cardiac disease characterized by significant arrhythmia, unstable ischemic coronary disease or congestive heart failure * known hiv infection * active second malignancy, aside from basal cell or squamous cell carcinoma of the skin * significant autoimmune disease, including psoriasis * history of clinically significant venous thromboembolism

Keywords: tumor harvest tumor collection tumor storage
aggression from the perspective of patients and nurses

Conditions: Aggression

Summary: the research, was planned in a randomized controlled design, aiming to evaluate the effect of the training given to nurses working in psychiatric clinics on the use of aggression and bvc (broset violence checklist) on the nurses' perceptions of aggression and the compliance of the use of bvc, which they evaluated for the patients watched in the videos, with the bvc determined by expert opinion. the study was conducted in adana doctor ekrem tok mental health and diseases hospital between july 2021 and april 2022. a total of 97 nurses working in psychiatric clinics, 47 in the training group and 50 in the comparison group, participated in the study. a pre-test was administered to the nurses and nurses in the training group were randomized and given training including aggression and bvc use. after the training, a post-test was administered to all nurses.


Eligibility criteria:
inclusion criteria: * volunteering to participate in the research, * to have been working in the hospital where the research was conducted for at least 1 year, * to have no vision, hearing and speech problems. exclusion criteria: * to want to withdraw from the research at any stage of the research, * not completing or not being able to complete the research for any reason, * to work in the filiation team during the research process.

Keywords: aggression aggression in psychiatry clinics perception of aggression risk level of violence
a study of askg915 in patients with selected advanced solid tumors.

Conditions: Advanced Solid Tumors

Summary: the study is a phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of askg915 as a single agent in patients with selected advanced solid tumors.

a two-part, dose-escalation and expansion study of askg915 was initiated to determine the safety, tolerability, pk and pd.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available. 2. ecog performance status of ≤ 2. 3. life expectancy of ≥ 3 months. 4. the results of the laboratory tests must meet all criteria. exclusion criteria: 1. patients have received antitumor therapy during the first 4 weeks before study drug use. 2. received a live attenuated vaccine within 4 weeks prior to c1d1. 3. known cerebral parenchymal metastasis or meningeal metastasis. 4. history of serious cardiovascular or cerebrovascular diseases. 5. active or recurrent autoimmune diseases. 6. history of ascites or pleural effusion requiring drainage. 7. pregnant or lactating or planning to become pregnant at any time during the study, including the follow-up period.
efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the nhipec trial)

Conditions: Hyperthermic Intraperitoneal Chemotherapy; Neoadjuvant Chemotherapy

Summary: background: neoadjuvant chemotherapy (nact) is an important treatment option for patients with ovarian cancer. although intravenous nact can improve optimal resection rates and decrease surgical morbidity and mortality, these advantages do not translate into a survival benefit. ovarian carcinoma is mainly confined to the peritoneal cavity, which makes it a potential target for hyperthermic intraperitoneal chemotherapy (hipec). our previous study showed that hipec could be used in the neoadjuvant setting, which was named neoadjuvant hipec (nhipec). since hyperthermia is an excellent chemosensitiser, we hypothesised that the combination of nhipec and intravenous nact could show superior efficacy to intravenous nact alone. methods: this study is a single-centre, open-label, randomised (1:1 allocation ratio) phase 2 trial. a total of 80 patients will be randomly assigned into an experimental group (nhipec+intravenous nact) or a control group (intravenous nact). patients in the experimental group will receive nhipec following laparoscopic evaluation, and four tubes will be placed via the laparoscopic ports, which will be used to administer nhipec. then, perfusion with docetaxel (60-75 mg/m2) will be performed (43°c for 60 min, day 0) followed by cisplatin (75 mg/m2, day 1) infusion (43°c for 60 min) 24 hours later. after nhipec, two cycles of intravenous nact will be given. patients in the control group will receive three cycles of intravenous nact. the primary endpoint is the proportion of patients who achieve a chemotherapy response score (crs) of 3 according to the crs system. the secondary endpoints include progression-free survival, overall survival and the rates of complete resection and nhipec-related adverse events.


Eligibility criteria:
inclusion criteria: 1. international federation of gynecology and obstetrics(figo) stage iiic-iva, hgsoc 2. patients with fagotti score ≥8 3. adequate kidney function (blood creatinine 58-96 µmol/l) 4. adequate haematological function (haemoglobin ≥110g/l, leucocytes ≥4.0×109/l, neutrophils ≥2.0×109/l, platelets≥100×109/l) 5. adequate liver function (serum total bilirubin 3.4-22.2µmol/l, alanine aminotransferase (alt) 7-40u/l, aspartate aminotransferase (ast) 13-35u/l, ast/alt ≤1.5) 6. world health organization(who) score 0-2 exclusion criteria: 1. patients who had received chemotherapy, radiotherapy or any kind of targeted therapy. 2. patients with complete intestine obstruction. 3. expected life span ≤8 weeks. 4. complicated with any other known malignancies. 5. patients with poor cardiopulmonary function, which would limit compliance with study requirements.

Keywords: hipec neoadjuvant chemotherapy high-grade serous ovarian cancer
influence of mild therapeutic hypothermia on leukocyte count

Conditions: Ventricular Fibrillation

Summary: mild therapeutic hypothermia is indicated in patients surviving out-of-hospital cardiac arrest due to ventricular fibrillation. potential immunologic responses are unknown.


Eligibility criteria:
inclusion criteria: * survivors of cardiac arrest due to vf * age 18-90 exclusion criteria: * suspected / proven pregnancy * immunodeficiency

Keywords: post resuscitation post ventricular fibrillation patients receiving mild therapeutic hypothermia
respond edge post market study

Conditions: Aortic Valve Stenosis

Summary: the purpose of the respond edge post market study is to collect real world clinical and device performance outcomes data with the lotus edge™ valve system used in routine clinical practice to demonstrate that the commercially available lotus edge valve system is a safe and effective treatment for patients with severe calcific aortic stenosis.

the respond edge study is a prospective, open label, single arm, multi-center, observational post market study designed to collect real world clinical and device performance outcomes data of the commercially available lotus edge valve used in routine clinical practice for the treatment of severe calcific aortic stenosis. approximately 200 real-world, consecutive subjects will be enrolled at up to 20 study centers. the study duration for each subject is expected to be approximately 2 years. implanted subjects will be contacted for follow-up at 30 days, 1 and 2 years post index procedure. subjects who are enrolled but not implanted with a lotus edge valve will be followed for safety through 30 days after the initial attempted index procedure. collection of safety events will include any serious adverse event (sae), serious adverse device effect (sade), adverse device effect (ade), unanticipated serious adverse device effect (usade), and all valve academic research consortium (varc) events regardless of seriousness and device relationship through 2 year follow-up.

Eligibility criteria:
subjects will be evaluated for eligibility by the clinical center's heart team per the local standard of practice in accordance with the directions for use.
hiv provider intervention to address intersectional stigma and medical mistrust

Conditions: Stigma, Social

Summary: intersectional stigma and medical mistrust are prevalent among black and latina/latino americans living with hiv and are key contributors to racial/ethnic health disparities; yet, there are no evidence-based provider-level interventions available for hiv care providers to address intersectional stigma and medical mistrust with patients. the investigators propose to develop an online provider intervention, with community stakeholders' input, that provides psychoeducation and skills-building around addressing intersectional stigma and medical mistrust with patients. the investigators will conduct a pilot randomized controlled trial with 60 hiv care physicians (30/condition) to test the acceptability and feasibility of the online intervention and to determine preliminary effects (against a no-intervention control group) on providers' use of skills and hiv care delivery outcomes at baseline, immediate post, and 6-month follow-up.

the first aim will be an intervention development process that involves engaging community stakeholders to incorporate their input on the intervention manual and working with a provider training organization to develop an online platform for the initial pilot testing. the intervention will include psychoeducation and skills-building for providers to address intersectional stigma and mistrust, tailored to hiv care. this aim will include a usability test of the online intervention in 10 hiv clinical care providers. the second aim will be to conduct a pilot randomized controlled trial to compare two conditions (i.e., online provider intervention versus no-intervention control) on provider training outcomes (e.g., providers' use of skills learned in the intervention) and hiv care delivery outcomes (e.g., the estimated percentage of patients lost to care in the past year) measured at baseline, immediate post-intervention, and 6-month follow-up. clinical providers (n = 60) providing care for patients living with hiv will be randomly assigned to the online provider intervention (n = 30) or control with no intervention (n = 30). the intervention will be delivered in groups (5-10 providers per group). a mixed-methods process evaluation at immediate post-intervention will determine the acceptability, feasibility, and appropriateness of the intervention, and will be used to refine the intervention.

Eligibility criteria:
inclusion criteria: * clinical providers (including physicians, physician assistants, nurse practitioners, registered nurses/case managers) caring for patients living with hiv, * the majority of their patients are from racial/ethnic and sexual minority groups, * can make the time commitment to participate in the study. exclusion criteria: * not hiv clinical providers * cannot make the time commitment to participate
unlocking dystonia from parkinson's disease with directional dbs technology

Conditions: Dystonia-Parkinsonism, Adult-Onset; Parkinson Disease

Summary: this study occurs during five visits that are already scheduled as part of "biomarkers to guide directional dbs for parkinson's disease" (clinicaltrials.gov identifier: nct03353688). if participants have dystonia associated with parkinson's disease, the investigators will consent and administer one additional rating scale (burke-fahn-marsden dystonia rating scale) to assess the severity of dystonia.

to measure the effects of dbs on dystonia, the investigators will measure the change in the burke-fahn-marsden dystonia rating scale at 2, 4, 6, and 12 months after surgery versus preoperative baseline. this will allow them to contrast the effects of omnidirectional versus directional stn dbs on dystonia symptoms in patients with pd.

Eligibility criteria:
inclusion criteria: * enrollment in "biomarkers to guide directional dbs for parkinson's disease" (clinicaltrials.gov identifier: nct03353688) * diagnosis of parkinson's disease with and without dystonia exclusion criteria: * not enrolled in "biomarkers to guide directional dbs for parkinson's disease" (clinicaltrials.gov identifier: nct03353688)

Keywords: dystonia parkinson's disease
alpha-bisabolol for onychomycosis treatment

Conditions: Onychomycosis

Summary: clinical, interventional, longitudinal study with random sampling. 60 patients will be divided into three groups, group a: control group, drug recommended by the brazilian society of dermatology, group b: alpha bisabolol-based product associated with low-level laser therapy, and group c: alpha bisabolol based product. the topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days. areas of the lesions will be compared.

introduction: onychomycosis is an infection caused by fungi that feed on keratin, a protein that makes up most of the nails. in patients with diabetes mellitus and onychomycosis, the risk of foot complications is a concern, especially for those who do not perform the practice of self-care of the skin, nails and feet in general correctly, which can trigger an important tissue damage that culminates in limb amputation. one of the alternatives for the treatment are herbal medicines. the application of alpha-bisabolol in the pharmaceutical sector is related to its anti-inflammatory, antispasmodic, antiallergic, drug permeation and deworming properties, having an important action in the morphology of dermatophytic fungal cells. objectives: develop and evaluate a pharmaceutical formula with alpha-bisololol for the treatment of onychomycosis. methods: clinical, interventional, longitudinal study with random sampling. the study will be held at the sthomatherapy clinic of the nursing care and teaching center at the samuel libânio hospital and at the dermatocare clinic stomatherapy and podiatry clinic, pouso alegre, mg. 60 patients with onychomycosis will participate in this study, which will be divided into three groups, group a: control group, drug recommended by the brazilian society of dermatology, group b: alpha bisabolol-based product associated with low-level laser therapy, and group c: alpha bisabolol based product. the topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days.

Eligibility criteria:
inclusion criteria: * volunteers with onychomycosis, * aged over 18 years. exclusion criteria: * volunteers have a known allergic process to topical treatment, and those who present an allergic reaction to alpha bisabolol * patients with a history of neoplasm in a location close to the nail plate, and patients with psoriasis. * volunteers who withdraw their consent at any time during the research, and those who present an allergic reaction to alpha bisabolol * pregnant women.

Keywords: onychomycosis phytotherapy laser therapy plant oils
huaier granule as adjuvant therapy for colorectal cancer after radical surgery

Conditions: Colorectal Cancer

Summary: a randomized, paralleled control clinical study investigating huaier granule for prevention of recurrence and metastasis of colorectal cancer after radical surgery, to evaluate the efficacy and safety.


Eligibility criteria:
inclusion criteria: * the subjects volunteer to sign the informed consent; * aged: 18 to 75 years old; * colorectal cancer (ajcc-tnm, stage ⅰ, low-risk stage ⅱand stage ⅲ; patients with stage ⅲ colorectal cancer refuse to postoperative adjuvant chemotherapy); * the diagnosis and colorectal cancer has been confirmed by pathological examination after radical surgery; * the liver and kidney function satisfies the following conditions within 15 days after surgery (excluding day 15): aspartate aminotransferase (ast), glutamic-oxalacetic transaminase (alt), alkaline phosphatase (alp)\< 2 upper limit of normal (uln), total bilirubin ≤ 1.5 uln, serum creatinine \< 1.5 uln; normal coagulation function; * other laboratory tests meet the following requirements within 15 days after surgery (excluding day 15): white blood cells count ≥ 3.0×109/l, absolute neutrophil count ≥ 1.5×109/l, platelet count ≥ 100×109/l; * ecog：0-2 points； * no other previous history of malignancy. exclusion criteria: * multiple primary cancer; * not recover from the colorectal surgery; * presence of organ, bone, or skin metastases; * pregnant or lactating women; * those with active bleeding due to various reasons; * those with hiv infection or aids-associated diseases; * those with severe acute and chronic diseases; * those with severe diabetes; * those with serious infectious diseases; * those who can not take drugs by oral route; * drug abusers or those with psychological or mental diseases that may interfere with study compliance; * conditions that are considered not suitable for this study investigators.

Keywords: huaier granule after radical surgery prevention of recurrence and metastasis efficacy and safety